Silo Pharma, Inc. (SILO) — SEC Filings
Silo Pharma, Inc. (SILO) — 45 SEC filings. Latest: EFFECT (Apr 16, 2026). Includes 22 8-K, 5 10-Q, 4 S-1.
View Silo Pharma, Inc. on SEC EDGAR
Overview
Silo Pharma, Inc. (SILO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B3 filed on Apr 14, 2026: Silo Pharma, Inc. filed a 424B3 prospectus on April 14, 2026, detailing its offerings. The filing, with SEC Accession Number 0001213900-26-043614, includes a prospectus document of 1304014 bytes. The company's mailing and business address is 677 N. Washington Blvd, Sarasota, FL 34236.
Sentiment Summary
Across 45 filings, the sentiment breakdown is: 4 bearish, 39 neutral, 2 mixed. The dominant filing sentiment for Silo Pharma, Inc. is neutral.
Filing Type Overview
Silo Pharma, Inc. (SILO) has filed 2 EFFECT, 1 424B3, 22 8-K, 5 10-Q, 4 S-1, 2 DEF 14A, 3 S-1/A, 2 10-K, 2 SC 13G, 1 SC 13G/A, 1 8-K/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (45)
Risk Profile
Risk Assessment: Of SILO's 38 recent filings, 5 were flagged as high-risk, 20 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $54,076 |
| Net Income | -$3,346,168 |
| EPS | -$0.50 |
| Debt-to-Equity | 0.27 |
| Cash Position | $3,917,627 |
| Operating Margin | -6463.0% |
| Total Assets | $6,384,681 |
| Total Debt | $1,375,841 |
Key Executives
- Eric Weisblum
- Richard Friedman, Esq.
Industry Context
Silo Pharma operates in the highly competitive and capital-intensive biopharmaceutical industry, characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. The industry is driven by innovation in therapeutic areas such as neurological disorders (PTSD, Alzheimer's, MS) and pain management (fibromyalgia). Diversification into cryptocurrency assets introduces an element of speculative technology, a departure from traditional pharma business models.
Top Tags
material-agreement (8) · filing (7) · 8-K (6) · sec-filing (5) · corporate-governance (5) · registration-statement (4) · equity-sale (4) · compliance (3) · Biopharmaceutical (3) · corporate-actions (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Prospectus Size | 1304014 bytes | Indicates the volume of information contained in the primary prospectus document. |
| SEC Accession Number | 0001213900-26-043614 | Unique identifier for this specific SEC filing. |
| Effectiveness Date | 2026-04-13 | The date the registration statement became effective. |
| Filing Date | 2026-04-14 | The date the SEC accepted the filing. |
| Net Loss | $3,346,168 | Increased from $2,662,260 in 2024 for the nine months ended September 30 |
| Research and Development Expenses | $1,854,824 | Increased 43.5% from $1,292,437 in 2024 for the nine months ended September 30 |
| License Fee Revenue | $54,076 | Remained flat for the nine months ended September 30, 2025 and 2024 |
| Cash Used in Operating Activities | $3,881,061 | For the nine months ended September 30, 2025 |
| Accumulated Deficit | $18,610,859 | As of September 30, 2025 |
| Working Capital | $5,456,030 | As of September 30, 2025 |
| Cash and Cash Equivalents | $3,917,627 | As of September 30, 2025 |
| Net Cash Provided by Financing Activities | $2,728,880 | For the nine months ended September 30, 2025 |
| Common Stock Shares Outstanding | 13,318,273 | As of November 13, 2025 |
| Shares of Common Stock | 3,071,428 | Maximum shares registered for resale upon warrant exercise |
| Investor Warrant Exercise Price | $0.75 | Price at which 2,857,143 Investor Warrants can be exercised |
Frequently Asked Questions
What are the latest SEC filings for Silo Pharma, Inc. (SILO)?
Silo Pharma, Inc. has 45 recent SEC filings from Jan 2024 to Apr 2026, including 22 8-K, 5 10-Q, 4 S-1. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SILO filings?
Across 45 filings, the sentiment breakdown is: 4 bearish, 39 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Silo Pharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Silo Pharma, Inc. (SILO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Silo Pharma, Inc.?
Key financial highlights from Silo Pharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SILO?
The investment thesis for SILO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Silo Pharma, Inc.?
Key executives identified across Silo Pharma, Inc.'s filings include Eric Weisblum, Richard Friedman, Esq..
What are the main risk factors for Silo Pharma, Inc. stock?
Of SILO's 38 assessed filings, 5 were flagged high-risk, 20 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Silo Pharma, Inc.?
Forward guidance and predictions for Silo Pharma, Inc. are extracted from SEC filings as they are enriched.